全文获取类型
收费全文 | 943590篇 |
免费 | 68951篇 |
国内免费 | 5885篇 |
专业分类
耳鼻咽喉 | 12960篇 |
儿科学 | 29016篇 |
妇产科学 | 26604篇 |
基础医学 | 130711篇 |
口腔科学 | 25428篇 |
临床医学 | 80668篇 |
内科学 | 188151篇 |
皮肤病学 | 19339篇 |
神经病学 | 73288篇 |
特种医学 | 38438篇 |
外国民族医学 | 358篇 |
外科学 | 147305篇 |
综合类 | 29403篇 |
现状与发展 | 6篇 |
一般理论 | 253篇 |
预防医学 | 67865篇 |
眼科学 | 21507篇 |
药学 | 69233篇 |
59篇 | |
中国医学 | 5314篇 |
肿瘤学 | 52520篇 |
出版年
2021年 | 8000篇 |
2019年 | 8184篇 |
2018年 | 10982篇 |
2017年 | 8931篇 |
2016年 | 9422篇 |
2015年 | 11352篇 |
2014年 | 15621篇 |
2013年 | 22321篇 |
2012年 | 30369篇 |
2011年 | 32085篇 |
2010年 | 19997篇 |
2009年 | 18505篇 |
2008年 | 29106篇 |
2007年 | 30626篇 |
2006年 | 30566篇 |
2005年 | 29844篇 |
2004年 | 27819篇 |
2003年 | 26757篇 |
2002年 | 26062篇 |
2001年 | 42111篇 |
2000年 | 43132篇 |
1999年 | 36749篇 |
1998年 | 9768篇 |
1997年 | 8903篇 |
1996年 | 8777篇 |
1995年 | 8686篇 |
1994年 | 8301篇 |
1993年 | 7699篇 |
1992年 | 28309篇 |
1991年 | 27112篇 |
1990年 | 26528篇 |
1989年 | 25433篇 |
1988年 | 23635篇 |
1987年 | 23235篇 |
1986年 | 22309篇 |
1985年 | 21201篇 |
1984年 | 15822篇 |
1983年 | 13472篇 |
1982年 | 8062篇 |
1979年 | 14580篇 |
1978年 | 10191篇 |
1977年 | 8604篇 |
1976年 | 8124篇 |
1975年 | 8945篇 |
1974年 | 10686篇 |
1973年 | 10174篇 |
1972年 | 9665篇 |
1971年 | 8911篇 |
1970年 | 8579篇 |
1969年 | 8021篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
Yilmaz Hülya Fırtına Sinem Sarıtaş Merve Sayitoğlu Müge Ar Muhlis Cem 《Immunologic research》2022,70(6):811-816
Immunologic Research - Hyper immunoglobulin M (HIGM) syndrome is a rare disorder of the immune system with impaired antibody functions. The clinical picture of the patients varies according to the... 相似文献
63.
Biaoming Xu Yu Chen Mingjing Peng Jin Hai Zheng Chaohui Zuo 《International journal of cancer. Journal international du cancer》2023,152(2):110-122
Pancreatic cancer (PC) is a cancer of the digestive system, and pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of all PC cases. Exosomes derived from PDAC (PDAC-exosomes) promote PDAC development and metastasis. Exosomes are nanoscale vesicles secreted by most cells, which can carry biologically active molecules and mediate communication and cargo transportation among cells. Recent studies have focused on transforming exosomes into good drug delivery systems (DDSs) to improve the clinical treatment of PDAC. This review considers PDAC as the main research object to introduce the role of PDAC-exosomes in PDAC development and metastasis. This review focuses on the following two themes: (a) the great potential of PDAC-exosomes as new diagnostic markers for PDAC, and (b) the transformation of exosomes into potential DDSs. 相似文献
64.
Journal of Assisted Reproduction and Genetics - 相似文献
65.
Cho Nicholas Wang Chencai Raymond Catalina Kaprealian Tania Ji Matthew Salamon Noriko Pope Whitney B. Nghiemphu Phioanh L. Lai Albert Cloughesy Timothy F. Ellingson Benjamin M. 《Journal of neuro-oncology》2020,147(3):643-652
Journal of Neuro-Oncology - There is growing evidence that the subventricular zone (SVZ) plays a key role in glioblastoma (GBM) tumorigenesis. However, little is known regarding how the SVZ, which... 相似文献
66.
Sanne C. F. A. Huijberts Robin M. J. M. van Geel Emilie M. J. van Brummelen Frans L. Opdam Serena Marchetti Neeltje Steeghs Saskia Pulleman Bas Thijssen Hilde Rosing Kim Monkhorst Alwin D. R. Huitema Jos H. Beijnen Ren Bernards Jan H. M. Schellens 《Cancer chemotherapy and pharmacology》2020,85(5):917-930
KRAS oncogene mutations cause sustained signaling through the MAPK pathway. Concurrent inhibition of MEK, EGFR, and HER2 resulted in complete inhibition of tumor growth in KRAS-mutant (KRASm) and PIK3CA wild-type tumors, in vitro and in vivo. In this phase I study, patients with advanced KRASm and PIK3CA wild-type colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic cancer, were treated with combined lapatinib and trametinib to assess the recommended phase 2 regimen (RP2R). Patients received escalating doses of continuous or intermittent once daily (QD) orally administered lapatinib and trametinib, starting at 750 mg and 1 mg continuously, respectively. Thirty-four patients (16 CRC, 15 NSCLC, three pancreatic cancers) were enrolled across six dose levels and eight patients experienced dose-limiting toxicities, including grade 3 diarrhea (n = 2), rash (n = 2), nausea (n = 1), multiple grade 2 toxicities (n = 1), and aspartate aminotransferase elevation (n = 1), resulting in the inability to receive 75% of planned doses (n = 2) or treatment delay (n = 2). The RP2R with continuous dosing was 750 mg lapatinib QD plus 1 mg trametinib QD and with intermittent dosing 750 mg lapatinib QD and trametinib 1.5 mg QD 5 days on/2 days off. Regression of target lesions was seen in 6 of the 24 patients evaluable for response, with one confirmed partial response in NSCLC. Pharmacokinetic results were as expected. Lapatinib and trametinib could be combined in an intermittent dosing schedule in patients with manageable toxicity. Preliminary signs of anti-tumor activity in NSCLC have been observed and pharmacodynamic target engagement was demonstrated. 相似文献
67.
68.
Shiyu Jiang Yan Qin Hongxin Jiang Biao Liu Jianming Shi Fanlu Meng Peng Liu Jianliang Yang Sheng Yang Xiaohui He Shengyu Zhou Lin Gui Hao Liu Jing Lin Han Han-Zhang Yuankai Shi 《International journal of cancer. Journal international du cancer》2020,147(9):2611-2620
Diffuse large B-cell lymphoma (DLBCL) is a clinically aggressive and heterogenous disease. Although most patients can be cured by immunochemotherapy, 30% to 40% patient will ultimately develop relapsed or refractory disease. Here, we investigated the molecular landscapes of patients with diverse responses to R-CHOP. We performed capture-based targeted sequencing on baseline samples of 105 DLBCL patients using a panel consisting of 112 lymphoma-related genes. Subsequently, 81 treatment-naïve patients with measurable disease and followed for over 1 year were included for survival analysis. Collectively, the most commonly seen mutations included IGH fusion (69%), PIM1(33%), MYD88 (29%), BCL2 (29%), TP53 (29%), CD79B (25%) and KMT2D (24%). Patients with TP53 mutations were more likely to have primary refractory disease (87.0% vs 50.0%, P = .009). For those with TP53 disruptive mutations, 91.7% patients were in the primary refractory group. Interestingly, BCL-2 somatic hypermutation was only seen in patients without primary refractory disease (P = .014). In multivariate analysis, BCL-2 amplification (hazard ratio [HR] = 2.94, P = .022), B2M mutation (HR = 2.99, P = .017) and TP53 mutation (HR = 3.19, P < .001) were independently associated with shorter time to progression (TTP). Furthermore, TP53 mutations was correlated with worse overall survival (P = .049). Next, we investigated mutation landscape in patients with wild-type (WT) TP53 (n = 58) and found that patients harboring MYD88 L265P had significantly inferior TTP than those with WT or non-265P (P = .046). Our study reveals the mutation spectrum of treatment-naive Chinese DLBCL patients. It also confirms the clinical significance of TP53 mutations and indicates the prognostic value of MYD88 L265P in TP53 WT patients. 相似文献
69.
70.